5 results
* To investigate the effect of roflumilast 500 µg tablets once daily versus placebo on exacerbation rate, and pulmonary function and major adverse cardiovascular events (MACE) in COPD patients who are concomitantly treated with a fixed combination…
The primary objective is to examine whether roflumilast (a PDE-4 inhibitor) can improve the cognition of healthy young volunteers. Secondary, we will assess the effects of roflumilast on electrophysiological correlates of cognition.
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Primary Objective(s):1. To determine whether aging associated cognitive impairment can be attenuated by roflumilast administration as assessed by cognitive battery tests.Secondary Objective(s):1. To determine whether brain electrical activity (ie,…
The primary objective of this study is to determine whether SAR439859 in combination with palbociclib improves progression free survival (PFS) compared to letrozole in combination with palbociclib in patients with ER +, HER2-advanced breast cancer…